Business Context and Reporting Period
Dare Bioscience, Inc. (Dare) filed a Form 8-K on April 30, 2018, reporting the entry into a Material Definitive Agreement. The filing details a proposed merger with Pear Tree Pharmaceuticals, Inc. (Pear Tree), a Delaware corporation.
Key Financial Metrics and Transaction Terms
The filing outlines the financial structure of the proposed merger rather than Dare's standalone operating results for the period. Key financial terms include:
- Cash Consideration at Closing: $75,000 plus Pear Tree's cash and cash equivalents at closing, less indebtedness, transaction expenses, and management incentive plan payments.
- Deferred Cash Consideration: $75,000 payable on the one-year anniversary of the closing, subject to offsets.
- Royalties: Tiered royalties based on percentages of annual net sales of licensed products and sublicense revenue.
- Milestone Payments: Contingent payments for clinical, regulatory, and commercial milestones, payable in cash or Dare common stock at Dare's discretion.
The filing text does not provide Dare's current revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Transaction Conditions
The primary material change is the execution of the Merger Agreement. Consummation of the transaction is subject to several closing conditions, including:
- Execution of non-solicitation and non-competition agreements by certain Pear Tree stockholders.
- Resignation of all Pear Tree employees, directors, and officers.
- Absence of any material adverse effect regarding Pear Tree.
- Stockholder approval regarding potential "parachute payments" under Section 280G of the Internal Revenue Code.
- Receipt of joinder agreements by specific Pear Tree stockholders.
Outlook, Risks, and Unusual Items
Outlook and Timeline: The transaction must be consummated by May 15, 2018, unless extended by mutual written consent. The full Merger Agreement is expected to be filed as an exhibit to Dare's Form 10-Q for the quarter ended June 30, 2018, with certain terms potentially under confidential treatment.
Risks and Contingencies: The agreement may be terminated by mutual consent, by Dare if consents are not received or a material adverse effect occurs, or by either party if representations are untrue or covenants are breached. The filing includes a disclaimer that representations and warranties are for risk allocation purposes and should not be relied upon as factual statements by stockholders.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement when filed with the Form 10-Q for the quarter ended June 30, 2018.
- Confirm whether the May 15, 2018 closing deadline is met or extended.
- Assess the impact of the transaction expenses and indebtedness deductions on the net cash consideration for Pear Tree.
- Monitor the status of required stockholder approvals and joinder agreements.
- Review Dare's upcoming financial reports for the impact of this acquisition on its balance sheet and cash position.